|
 A CME Symposium during the 2026 Heart Failure Management Conference in Fernandina Beach, Florida.
AGENDA
8:00 am Introduction
Muthiah Vaduganathan, MD, MPH (Chair)
8:05 am Hyperkalemia and Heart Failure: Impact of Continuation/Discontinuation of RAASi Therapy
Akshay Desai, MD, MPH
8:20 am Treating Hyperkalemia and Optimizing RAASi in HF Patients with Potassium Binders
Muthiah Vaduganathan, MD, MPH
8:35 am Best Strategies for Managing My HFrEF Patient with Elevated Potassium and a History of Hyperkalemia
Case Presenter: Robert Page, PharmD, MSPH, BCPS, BCGP
Panelists: Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC; Akshay Desai, MD, MPH; Muthiah Vaduganathan, MD, MPH
8:50 am Question-and-Answer
EDUCATIONAL OBJECTIVES
• Recognize heart failure patients at risk for developing hyperkalemia
• Describe the relationship between hyperkalemia, suboptimal RAASi therapy and poor clinical outcomes
• Explain the data with, and demonstrate prudent use of novel potassium binders
Educational Grant
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.
CHAIR
Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Assistant Professor of Medicine
Mass General Brigham and Harvard Medical School
Boston, Massachusetts
FACULTY
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC
Associate Chief Nursing Officer--Research and Innovation
Clinical Nurse Specialist--Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, Ohio
Akshay Desai, MD, MPH
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Robert Page, PharmD, MSPH, BCPS, BCGP
Professor, Departments of Clinical Pharmacy and Physical Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences
CU Anschutz
Aurora, Colorado
|
Monthly View
Flat View
Weekly View
Daily View
Categories